NXL NEXALIN TECHNOLOGY INC

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries.

Attendees will have the opportunity to engage with Nexalin’s management team and learn about its proprietary, non-invasive neurostimulation — a drug-free, clinically proven treatment with the potential to scale worldwide.

For additional information about the Maxim Growth Summit, or to register for the event, please click .

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: .

Contact:

Crescendo Communications, LLC

Tel: (212) 671-1020

Email:



EN
10/10/2025

Underlying

NXLNEXALIN TECHNOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXALIN TECHNOLOGY INC

 PRESS RELEASE
Free
NXL NEXALIN TECHNOL...

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De No...

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market 150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed Clinical Data and International Regulatory Approvals HOUSTON, TX, Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced continued adva...

February 24, 2026 1 EN
 PRESS RELEASE
Free
NXL NEXALIN TECHNOL...

Nexalin Participates in and Commends Recent Congressional Momentum Sup...

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease HOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NXL) (the “Company” or “Nexalin”), developer of Deep Intracranial Frequency Stimulation (DIFS™) technology for non-invasive deep brain stimulation, commended the recent series of bipartisan Congressional initiatives expand...

February 23, 2026 1 EN
 PRESS RELEASE
Free
NXL NEXALIN TECHNOL...

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to T...

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disorders HOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the launch of...

February 5, 2026 1 EN
 PRESS RELEASE
Free
NXL NEXALIN TECHNOL...

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Re...

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigoro...

February 2, 2026 1 EN
 PRESS RELEASE
Free
NXL NEXALIN TECHNOL...

Nexalin Technology Receives Nasdaq Listing Status Notification

Nexalin Technology Receives Nasdaq Listing Status Notification HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a notification letter (the "Notification Letter") from the Nasdaq Stock Market LLC (the "NASDAQ") dated January 21, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on the...

January 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch